Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9466555 | 0.99 | SIGMAR1 (0.41) | SIGMAR1GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL8691572 | 0.83 | GRM2 (0.35) | SIGMAR1SLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL6739578 | 0.80 | SIGMAR1 (0.41) | SIGMAR1GBA1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2688223 | 0.80 | GRIN2B (0.55) | SIGMAR1KMT2AGRM2 | |
| SCHEMBL8303444 | 0.78 | SIGMAR1 (0.55) | SIGMAR1KMT2A | |
| SCHEMBL9179397 | 0.76 | SIGMAR1 (0.55) | SIGMAR1 | |
| SCHEMBL873444 | 0.76 | SLC6A2 (0.50) | GBA1SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL2186411 | 0.76 | SLC6A2 (0.50) | GBA1SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL51254 | 0.76 | SLC6A2 (0.50) | GBA1SLC6A4SLC6A2SLC6A3KMT2A | |
| SCHEMBL8759775 | 0.75 | GRM2 (0.32) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149087-B1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-6596722-B2 | Serotonin reuptake inhibitors/HT3 receptor antagonists useful for treatment of depression, psychosis, anxiety disorders, panic disorder, obsessive compulsive disorder, and eating disorders | H. LUNDBECK A/S (DK) | 2003-07-22 | — | — | US | disclosed |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S | 2002-11-21 | — | — | US | disclosed |
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
| EP-1149087-A1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. Lundbeck A/S (DK) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000043382-A1 | PIPERIDINE, TETRAHYDROPYRIDINE AND PIPERAZINE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-07-27 | — | — | WO | disclosed |
| EP-0574313-B1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR (FR) | 1999-10-06 | — | — | EP | disclosed |
| US-5789412-A | 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR ANTAGONISTS FOR THE CURATIVE OR PREVENTIVE TREATMENT OF PAIN, DEPRESSION, OBSESSIVE COMPULSIVE DISORDERS, ANXIETY OR PANIC ATTACK, OR CANCER | PIERRE FABRE MEDICAMENT (FR) | 1998-08-04 | — | — | US | disclosed |
| EP-0773937-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002525-A1 | NOVEL ARYL PIPERAZINE-DERIVED PIPERAZIDE DERIVATIVES, METHODS FOR THEIR PREPARATION, THEIR USE AS DRUGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | PIERRE FABRE MEDICAMENT (FR) | 1996-02-01 | — | — | WO | disclosed |
| US-5464834-A | Antidepressants, central nervous system | ADIR ET COMPAGNIE (FR) | 1995-11-07 | — | — | US | disclosed |
| EP-0490772-B1 | 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them | ADIR (FR) | 1995-07-26 | — | — | EP | disclosed |
| EP-0574313-A1 | 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-12-15 | — | — | EP | disclosed |
| US-5194437-A | Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders | ADIR ET COMPAGNIE (FR) | 1993-03-16 | — | — | US | disclosed |
| EP-0490772-A1 | 1,4-Disubstituted piperazines, their process of preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035113-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | SIGMAR1 397/4885GBA1 2423/4885SLC6A4 635/4885 |
| US-20020173512-A1 | Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use | DRD1, DRD2, H1-5 | SIGMAR1 397/4885GBA1 2423/4885SLC6A4 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.